Cost-effective treatment of coronary artery disease - The new imperative

Clinical Cardiology

Volumn 19, Issue 8, 1996, Pages 650-655

  Superko, H Robert ^a,b  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b Genet Heart Dis Inst   (United States)

Author keywords

cholesterol; cost analysis; lipoprotein subclass; lipoproteins; low density lipoprotein cholesterol; small low density lipoprotein

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL METABOLISM; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HUMAN; PATIENT CODING; PRIMARY PREVENTION; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 0029832458     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960190813     Document Type: Article

References (40)

1. Lisser ED: Number of major cardiac surgeries was nearly flat in 1993, survey finds. Wall Street Journal, Oct 3, 1994, B10
2. Roberts WC: Retail costs of the statin lipid-lowering drugs. Am J Cardiol 1994;74:1181
3. Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J Am Med Assoc 1984;251:351-364
4. Frick MH, Elo O, Haapa K, Heinonen P, Heinsalmi P, Helo P, Huttenen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA: Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-1245
5. Coronary Drug Project Research Group: Natural history of myocardial infarction in the coronary drug project: Long-term prognostic importance of serum lipid levels. Am J Cardiol 1978;42: 489-498
6. Canner PL, Berge KG, Wenger NK, Stander J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255
7. Superko HR, Krauss RM: Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056-1069
8. Shepherd J, Cobbe SM, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
9. McBride PE, Davis JE: Cholesterol and cost-effectiveness. Circulation 1992;85:1939-1941
10. Superko HR: Drug therapy and the prevention of atherosclerosis in humans. Am J Cardiol, 1989;64:31G-38G
11. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;349:1383-1389
12. Pitt B, Mancini J, Ellis SG, Rosman HS, Park JS, McGovern ME, and the PLAC I Investigators: Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Am Coll Cardiol 1995; 26:1133-1139
13. Jukema JW, Bruschke VG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI, and the REGRESS Study Group: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels (REGRESS). Circulation 1995;91:2528-2540
14. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85:37-45
15. Campos CT, Nguyen P, Buchwald, and the POSCH Group: Effect of cholesterol lowering on PTCA, CABG, and heart transplantation rates: POSCH lone-term follow-up study. Circulation 1993;88:I-386
16. Watts GF, Mandalia S, Brunt JN, Slavin BM, Coltart DJ, Lewis B: Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St Thomas' Atherosclerosis Regression Study (STARS). Metabolism 1993;42: 1461-1467
17. Cashin-Hemphill L, Mack W, LaBree L, Hodis HN, Shircore A, Selzer RH, Blankenhorn DH: Coronary progression predicts future cardiac events. Circulation 1993;88:I-363
18. Alderman EL, Haskell WL, Fair JM, Superko HR, Maron DJ, Champagne MA, Mackey SF, Williams PT, Krauss RM, Farquhar JW: Beneficial angiographic and clinical response to multifactor modification in the Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994;89:975-990
19. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DS, Kinosian B, Weinstein MC: Cost and health implications of cholesterol lowering. Circulation 1992;85:1960-1968
20. Scott WG, White HD, Scott HM: Cost of coronary heart disease in New Zealand. NZ Med J 1993;106:347-349
21. Waters D, Craven TE, L'Esperance J: Prognostic significance of progression of coronary atherosclerosis. Circulation 1993;87: 1067-1075
22. Phillips NR, Waters D, Havel RJ: Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770
23. Superko HR: New aspects of cardiovascular risk factors including small, dense LDL, homocysteinemia, and Lp(a). CurrOpin Cardiol 1995;10:347-354
24. Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-349
25. Slyper AH: Low-density lipoprotein density and atherosclerosis. Unraveling the connection. J Am Med Assoc 1994;272:305-308
26. Nishina PM, Johnson JP, Naggert JK, Krauss RM: Linkage of atherogenic lipoprotein phenotype to the low-density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 1992;89:708-712
27. Rotter JI, Bu X, Cantor R, Warden CH, Zia YR, De Meester C, Teryua S, Lockensgard B, Daneshmand S, Brown J, Gray RJ, Krauss RM, Lusus AJ: Multilocus genetic determination of LDL particle size in coronary artery disease families (abstr). Clin Res 1994;42:16A
28. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988;260:1917-1921
29. Krauss RM, Stampfer MJ, Blanche PJ, Holl LG, Ma J, Hennekens CH: Particle diameter and risk of myocardial infarction (abstr). Circulation 1994;90:I-460
30. Tornvall P, Bavenholm P, Landou C, Faire U, Hamsten A: Relation of plasma levels and composition of apolipoprotein B containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88: 2180-2189
31. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI: Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;11:62-65
32. Miller BD, Krauss RM, Cashin-Hemphill L, Blankenhorn DH: Baseline triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the Cholestero-Lowering Atherosclerosis Study (CLAS). Circulation 1993;88:I-363
33. Krauss RM, Miller BD, Fair JM, Haskell WL, Alderman EL, and the SCRIP staff: Reduced progression of coronary artery disease with risk factor intervention in patients with LDL subclass pattern B. Circulation 1992;86(suppl):1-63
34. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, DeBoer WV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ, and the MARS Research Group: Coronary angiographic changes with lovastatin therapy. Ann Intern Med 1993;119:969-976
35. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH: Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49
36. Miller BD, Cashin-Hemphill L, Mack WJ, Hodis HN, Krauss RM: Predominance of mid-density low-density lipoproteins predicts angiographic benefit of lovastatin in the Monitored Atherosclerosis Regression Study. Circulation 1994;90:I-460
37. Goldman L, Weinstein MC, Goldman PA, Williams LW: Cost effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart diseases. J Am Med Assoc 1991;265:1145-1151
38. Schulman K, Kinosian B, Jacobson T, Glick H, Eisenberg JM: Reducing high blood cholesterol with drugs: Cost effectiveness of pharmacologic management. J Am Med Assoc 1990;264:3025-3033
39. Spencer R: The internal mammary artery: The ideal coronary bypass graft? N Engl J Med 1986;31:50-51
40. Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IF: Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): In-hospital results and 1 year follow-up. J Am Coll Cardiol 1993;22:1060-1067